tldrdailynews.com logo

"Novo Nordisk Strikes Billion-Dollar Deals with Biotechs to Accelerate Obesity Drug Development"

1 min read
Source: STAT
"Novo Nordisk Strikes Billion-Dollar Deals with Biotechs to Accelerate Obesity Drug Development"
Photo: STAT
TL;DR

Novo Nordisk is expanding its obesity treatment portfolio by partnering with two Flagship Pioneering startups, Omega Therapeutics and Cellarity, to develop an mRNA-based obesity drug and a new medication for metabolic-associated fatty liver disease (MASH), respectively. These collaborations mark the first initiatives under a partnership agreement between Flagship and Novo Nordisk established in 2022.

Topics:businesshealth-and-pharmaceuticals##biotechpartnerships#flagshippioneering#health-and-pharmaceuticals#mash#novonordisk#obesitydrug
Share this article
  1. Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs  STAT
  2. Novo Signs $1.1 Billion Obesity R&D Deals With Two Biotechs  Yahoo Finance
  3. Omega Therapeutics stock more than doubles on Novo Nordisk obesity drug research pact  MarketWatch
  4. Omega (NASDAQ:OMGA) Skyrockets After Research Deal With Novo Nordisk - TipRanks.com  TipRanks
  5. Novo Nordisk signs deals worth up to $1bn with US biotechs in race for obesity drugs  Financial Times

Want the full story? Read the original reporting

Read on STAT